We are live on ! Find out more
TCIM

TIAA CREF Investment Management Portfolio holdings

AUM $141B
1-Year Est. Return 14.18%
This Fund
S&P 500
This Quarter Est. Return
-13.82%
1 Year Est. Return
+14.18%
3 Year Est. Return
+70.08%
5 Year Est. Return
+108.37%
10 Year Est. Return
AUM
$126B
AUM Growth
-$26.9B
Cap. Flow
-$3.01B
Cap. Flow %
-2.39%
Top 10 Hldgs %
19.4%
Holding
3,092
New
38
Increased
894
Reduced
1,823
Closed
85

Top Buys

Rank Stock Value
1
LIN icon
Linde
LIN
+$534M
2
META icon
Meta Platforms (Facebook)
META
+$198M
3
PG icon
Procter & Gamble
PG
+$186M
4
CVX icon
Chevron
CVX
+$182M
5
WFC icon
Wells Fargo
WFC
+$173M

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$335M
2
PX
Praxair Inc
PX
+$329M
3
AET
Aetna Inc
AET
+$251M
4
FDX icon
FedEx
FDX
+$206M
5
AMZN icon
Amazon
AMZN
+$205M

Sector Composition

Rank Sector Weight
1 Technology 19.73%
2 Healthcare 14.8%
3 Financials 14.65%
4 Consumer Discretionary 11.59%
5 Industrials 9.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AKAO
2976
DELISTED
Achaogen Inc
AKAO
$83K ﹤0.01%
67,274
CRVS icon
2977
Corvus Pharmaceuticals
CRVS
$1.17B
$80K ﹤0.01%
21,913
-732
-3% -$4.99K
PFSW
2978
DELISTED
PFSweb, Inc.
PFSW
$79K ﹤0.01%
15,470
-809
-5% -$5.2K
MBII
2979
DELISTED
Marrone Bio Innovations, Inc.
MBII
$78K ﹤0.01%
52,912
CTIC
2980
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$78K ﹤0.01%
105,668
-3,390
-3% -$5.57K
RMNI icon
2981
Rimini Street
RMNI
$471M
$77K ﹤0.01%
14,995
ZOM
2982
DELISTED
Zomedica Corp.
ZOM
$74K ﹤0.01%
60,529
ASUR icon
2983
Asure Software
ASUR
$250M
$73K ﹤0.01%
14,292
CELH icon
2984
Celsius Holdings
CELH
$7.03B
$72K ﹤0.01%
62,358
-23,499
-27% -$29.6K
FENC icon
2985
Fennec Pharmaceuticals
FENC
$402M
$68K ﹤0.01%
10,633
SNNA
2986
DELISTED
Sienna Biopharmaceuticals, Inc.
SNNA
$68K ﹤0.01%
29,164
-624
-2% -$5.5K
ADMA icon
2987
ADMA Biologics
ADMA
$2.22B
$63K ﹤0.01%
26,291
-1,085
-4% -$5.37K
NEXT icon
2988
NextDecade
NEXT
$1.78B
$63K ﹤0.01%
11,728
NMTR
2989
DELISTED
9 Meters Biopharma
NMTR
$60K ﹤0.01%
1,296
IMH
2990
DELISTED
Impac Mortgage Holdings Inc.
IMH
$60K ﹤0.01%
15,839
-47
-0.3% -$231
EPE
2991
DELISTED
EP Energy Corporation
EPE
$59K ﹤0.01%
83,932
MBIO icon
2992
Mustang Bio
MBIO
$4.55M
$58K ﹤0.01%
26
IBRX icon
2993
ImmunityBio
IBRX
$8.1B
$57K ﹤0.01%
49,252
NL icon
2994
NLI Holdings
NL
$317M
$56K ﹤0.01%
15,833
OVID icon
2995
Ovid Therapeutics
OVID
$491M
$56K ﹤0.01%
23,069
XFOR icon
2996
X4 Pharmaceuticals
XFOR
$460M
$54K ﹤0.01%
+128
New +$48.8K
PFIE
2997
DELISTED
Profire Energy, Inc
PFIE
$53K ﹤0.01%
36,280
CLSD
2998
DELISTED
Clearside Biomedical
CLSD
$51K ﹤0.01%
3,199
AMPE
2999
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$48K ﹤0.01%
406
FCEL icon
3000
FuelCell Energy
FCEL
$1.63B
$42K ﹤0.01%
211

Similar funds

TIAA CREF Investment Management's Q4 2018 Portfolio in Review

As of Q4 2018, TIAA CREF Investment Management held 3,092 positions worth $126B, down 18% from $153B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Trading was light in Q4 2018: portfolio turnover was 4%. TIAA CREF Investment Management opened 38 new positions and exited 85, leaving the 3,092-position portfolio largely intact.

By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 21% a quarter earlier, followed by Healthcare and Financials.

  • TIAA CREF Investment Management's largest Q4 2018 buy was Linde: 3,376,089 shares worth $527M.
  • TIAA CREF Investment Management added most to Meta Platforms (Facebook) in Q4 2018, an estimated $198M increase.
  • TIAA CREF Investment Management's biggest Q4 2018 reduction was Apple, cutting an estimated $335M.
  • TIAA CREF Investment Management fully exited Praxair Inc in Q4 2018, selling an estimated $329M.
  • TIAA CREF Investment Management's ten largest holdings make up 19% of its $126B portfolio in Q4 2018.
  • TIAA CREF Investment Management opened 38 new positions and closed 85 in Q4 2018.
  • TIAA CREF Investment Management's portfolio value fell 18% quarter-over-quarter to $126B.

Based on TIAA CREF Investment Management's 13F filing for Q4 2018, filed 14 Feb 2019.